Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

AVT02 · Abrilada, Amjevita

Monoclonal antibody · Antagonist of tumor necrosis factor alpha (TNF) · developed by Abbvie

Approved FDA, Dec 2002
1 Registered trials

What is AVT02?

AVT02 is an adalimumab product that binds TNF-alpha and blocks its interaction with the p55 and p75 TNF receptors.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Abrilada, Amjevita, Cyltezo, Yuflyma
Drug type
Monoclonal antibody
Targets
tumor necrosis factor alpha (TNF)
Mechanism
Antagonist of tumor necrosis factor alpha (TNF)
Pathways
TNF-induced adhesion molecule expression (ELAM-1, VCAM-1, ICAM-1), complement-dependent lysis of TNF-expressing cells
Therapy area
Immunology
Developer
Abbvie Inc
In trials of
ALVO
FDA status
Approved as Abrilada, Amjevita, Cyltezo (December 31, 2002), BLA125057 · FDA label

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03579823 Phase 1 Healthy Volunteers Completed ALVO

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Healthy Volunteers

Other drugs acting on TNF

Sources

Updated Nov 8, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.